Cargando…
Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Libbey Eurotext
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572685/ https://www.ncbi.nlm.nih.gov/pubmed/34463279 http://dx.doi.org/10.1684/ejd.2021.4087 |
| _version_ | 1784595264486506496 |
|---|---|
| author | Vinaixa Aranzazu, Arrieta Morillas-Lahuerta, Víctor Blanco De Tord, María Carrascosa Carrillo, José-Manuel |
| author_facet | Vinaixa Aranzazu, Arrieta Morillas-Lahuerta, Víctor Blanco De Tord, María Carrascosa Carrillo, José-Manuel |
| author_sort | Vinaixa Aranzazu, Arrieta |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8572685 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Libbey Eurotext |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85726852021-11-08 Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient Vinaixa Aranzazu, Arrieta Morillas-Lahuerta, Víctor Blanco De Tord, María Carrascosa Carrillo, José-Manuel Eur J Dermatol Correspondence John Libbey Eurotext 2021-11-08 2021 /pmc/articles/PMC8572685/ /pubmed/34463279 http://dx.doi.org/10.1684/ejd.2021.4087 Text en © JLE/Springer 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correspondence Vinaixa Aranzazu, Arrieta Morillas-Lahuerta, Víctor Blanco De Tord, María Carrascosa Carrillo, José-Manuel Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| title | Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| title_full | Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| title_fullStr | Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| title_full_unstemmed | Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| title_short | Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| title_sort | ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572685/ https://www.ncbi.nlm.nih.gov/pubmed/34463279 http://dx.doi.org/10.1684/ejd.2021.4087 |
| work_keys_str_mv | AT vinaixaaranzazuarrieta ixekizumabforthetreatmentoferythrodermicpsoriasistriggeredbydurvalumabtremelimumabinacancerpatient AT morillaslahuertavictor ixekizumabforthetreatmentoferythrodermicpsoriasistriggeredbydurvalumabtremelimumabinacancerpatient AT blancodetordmaria ixekizumabforthetreatmentoferythrodermicpsoriasistriggeredbydurvalumabtremelimumabinacancerpatient AT carrascosacarrillojosemanuel ixekizumabforthetreatmentoferythrodermicpsoriasistriggeredbydurvalumabtremelimumabinacancerpatient |